155 related articles for article (PubMed ID: 20451736)
1. Editorial comment.
Tan WW
Urology; 2010 May; 75(5):1143. PubMed ID: 20451736
[No Abstract] [Full Text] [Related]
2. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
[TBL] [Abstract][Full Text] [Related]
3. Re: The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
Griebling TL
J Urol; 2011 Apr; 185(4):1279. PubMed ID: 22098960
[No Abstract] [Full Text] [Related]
4. Harms versus benefits with duration of androgen suppression.
Nguyen PL
Lancet Oncol; 2012 Dec; 13(12):1182-3. PubMed ID: 23151430
[No Abstract] [Full Text] [Related]
5. Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
Cai T; Bartoletti R
J Clin Oncol; 2007 Aug; 25(22):3385; author reply 3385-6. PubMed ID: 17664492
[No Abstract] [Full Text] [Related]
6. Re: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer: C. W. Ryan, D. Huo, L. M. Demers, T. M. Beer and L. V. Lacerna. J Urol 2006; 176: 972-978.
Gilbert SM; Dunn RL; Wei JT
J Urol; 2007 Apr; 177(4):1584-5; author reply 1585. PubMed ID: 17382782
[No Abstract] [Full Text] [Related]
7. The opportunity cost of androgen suppression in locally advanced prostate cancer.
Gray PJ; Efstathiou JA; Shipley WU
Asian J Androl; 2013 May; 15(3):356-7. PubMed ID: 23435474
[No Abstract] [Full Text] [Related]
8. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
[TBL] [Abstract][Full Text] [Related]
9. [Prevention and treatment of osteoporosis during treatment of non-metastatic prostate cancer].
Eiken PA; Langdahl BL; Eiken FL; Walter S; Poulsen MH; Abrahamsen B
Ugeskr Laeger; 2011 Nov; 173(48):3093-6. PubMed ID: 22118650
[TBL] [Abstract][Full Text] [Related]
10. Annual zoledronic acid: is less more?
Higano CS
J Clin Oncol; 2007 Mar; 25(9):1026. PubMed ID: 17369565
[No Abstract] [Full Text] [Related]
11. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of prostate cancer].
Romics I
Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076
[No Abstract] [Full Text] [Related]
13. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
[TBL] [Abstract][Full Text] [Related]
14. Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Hershman D; Narayanan R
Curr Oncol Rep; 2004 Jul; 6(4):277-84. PubMed ID: 15161581
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
[TBL] [Abstract][Full Text] [Related]
16. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
Wadhwa VK; Weston R; Parr NJ
BJU Int; 2010 Apr; 105(8):1082-8. PubMed ID: 19912210
[TBL] [Abstract][Full Text] [Related]
17. Bone Health in Men with Prostate Cancer: Review Article.
A M El Badri S; Salawu A; Brown JE
Curr Osteoporos Rep; 2019 Dec; 17(6):527-537. PubMed ID: 31760582
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
Miki T; Okihara K
Nihon Rinsho; 2007 Nov; 65 Suppl 9():632-5. PubMed ID: 18161177
[No Abstract] [Full Text] [Related]
19. Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence?
Reddy SV; Gupta SK
Singapore Med J; 2012 Mar; 53(3):e52-4. PubMed ID: 22434305
[TBL] [Abstract][Full Text] [Related]
20. Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Pitts WR
J Urol; 2003 Dec; 170(6 Pt 1):2392-3; author reply 2393-4. PubMed ID: 14634434
[No Abstract] [Full Text] [Related]
[Next] [New Search]
